Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(1.05) per share which beat the analyst consensus estimate of $(1.35) by 22.22 percent. This is a 33.54 percent increase over losses of $(1.58) per share from the same period last year. The company reported quarterly sales of $16.96 million which missed the analyst consensus estimate of $17.25 million by 1.68 percent. This is a 5.80 percent decrease over sales of $18.00 million the same period last year.